Highlights

  • FY2026 revenue reached NZ$1.72 million, an increase of 37.9% on the previous financial year.
  • The company reported a FY2026 net loss after tax of NZ$1.84 million.
  • Commercial activity centred on antimicrobial formulations used in fresh-food packaging and other surface applications.
  • July 2026 sales totalled an unaudited NZ$625,000, according to the FY2026 annual report.
  • Year-end cash stood at NZ$268,120; the company identified customer receipts as a working-capital dependency.

Zoono Group Limited (ASX:ZNO) develops and distributes antimicrobial products and surface-treatment technologies used across hygiene, packaging and other commercial settings. Its FY2026 disclosures place particular emphasis on shelf-life extension for fresh produce, including formulations applied to food packaging. The results show higher sales and continued operating losses as the business works to convert product trials and supply agreements into recurring orders.

How the Surface-Treatment Technology Works

Zoono describes its technology as a surface-bonding antimicrobial treatment designed to form a persistent protective layer after application. The company markets formulations for surfaces, textiles and other materials, while its food-packaging activities focus on treated containers and packaging substrates. Performance depends on formulation, surface and application conditions.

For Zoono Group Limited (ASX:ZNO), the distinction between laboratory efficacy and commercial use is material. Packaging customers require repeatable treatment methods and evidence relevant to their individual products and supply chains. The company reported continuing testing against recognised ISO and EN standards in its FY2026 annual report.

FY2026 Financial Performance

Zoono Group Limited (ASX:ZNO) recorded revenue of NZ$1,723,819 for the year ended 30 June 2026, representing growth of NZ$473,686, or 37.9%. The annual report attributed the increase mainly to shelf-life extension sales in Australia, South Africa and the United Kingdom. Gross profit reached NZ$1,262,201, while the reported EBITDA loss was approximately NZ$1.65 million.

The group recorded a FY2026 net loss after tax of NZ$1,844,552 and reported NZ$268,120 in cash at 30 June 2026. Operating cash flow was negative NZ$1,540,365. These figures illustrate why customer receipts, expense control and order timing remain relevant to the company’s funding position. The company stated that its business objectives depend in part on future sales and cash collections.

Packaging Contracts and Commercial Activity

During FY2026, Zoono Group Limited (ASX:ZNO) advanced supply arrangements with packaging businesses serving fresh-produce markets. Its annual report described a further order of approximately NZ$600,000 received from UK packaging customer Sharpak in July 2026. It also reported recurring orders from South African packaging customer Mpact, including a third order valued at approximately NZ$122,000.

Trials continued in other locations and packaging formats, covering additional fresh produce and other perishable products. Trials and supply agreements are not necessarily recognised revenue. In its annual report, Zoono disclosed unaudited sales of NZ$625,000 for July 2026.

Operating Risks and Legal Proceedings

Adoption of antimicrobial packaging treatments depends on customer testing, manufacturing integration, repeat orders and applicable food-contact requirements. Zoono Group Limited (ASX:ZNO) also faces working-capital risk if receipts are delayed or commercial volumes develop more slowly than planned. Results from specific tests cannot automatically be extended to every treated surface or pathogen.

The FY2026 annual report further disclosed proceedings brought by the New Zealand Commerce Commission concerning allegedly unsubstantiated representations about certain hand-sanitiser and surface-spray products. The company disputes the allegations and said it intends to defend the case. This matter is distinct from the reported food-packaging sales and should be assessed separately.

Key Insights

Zoono Group Limited (ASX:ZNO) entered FY2027 after reporting increased FY2026 revenue and initial repeat orders within its packaging customer base. The immediate operational measures are subsequent customer deliveries, conversion of trials into commercial sales, cash generation and resolution of the disclosed legal proceedings. The company’s reported figures do not establish that the coating technology will achieve identical outcomes across different applications.